These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Adverse reactions with 3,4-methylenedioxymethamphetamine (MDMA; 'ecstasy'). McCann UD; Slate SO; Ricaurte GA Drug Saf; 1996 Aug; 15(2):107-15. PubMed ID: 8884162 [TBL] [Abstract][Full Text] [Related]
4. Pharmacological aspects of the combined use of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) and gamma-hydroxybutyric acid (GHB): a review of the literature. Uys JD; Niesink RJ Drug Alcohol Rev; 2005 Jul; 24(4):359-68. PubMed ID: 16234132 [TBL] [Abstract][Full Text] [Related]
5. Neurotoxicity of MDMA: Main effects and mechanisms. Costa G; Gołembiowska K Exp Neurol; 2022 Jan; 347():113894. PubMed ID: 34655576 [TBL] [Abstract][Full Text] [Related]
6. Malignant hyperpyrexia in an MDMA ("Ecstasy") abuser. McCoy EP; Renfrew C; Johnston JR; Lavery G Ulster Med J; 1994 Apr; 63(1):103-7. PubMed ID: 8658983 [No Abstract] [Full Text] [Related]
7. Neurotoxicity of methylenedioxyamphetamines (MDMA; ecstasy) in humans: how strong is the evidence for persistent brain damage? Gouzoulis-Mayfrank E; Daumann J Addiction; 2006 Mar; 101(3):348-61. PubMed ID: 16499508 [TBL] [Abstract][Full Text] [Related]
8. Memory performance in polyvalent MDMA (ecstasy) users who continue or discontinue MDMA use. Gouzoulis-Mayfrank E; Fischermann T; Rezk M; Thimm B; Hensen G; Daumann J Drug Alcohol Depend; 2005 Jun; 78(3):317-23. PubMed ID: 15893163 [TBL] [Abstract][Full Text] [Related]
10. The dark side of ecstasy: neuropsychiatric symptoms after exposure to 3,4-methylenedioxymethamphetamine. Karlsen SN; Spigset O; Slørdal L Basic Clin Pharmacol Toxicol; 2008 Jan; 102(1):15-24. PubMed ID: 18047478 [TBL] [Abstract][Full Text] [Related]
11. Neurological and cognitive alterations induced by MDMA in humans. Montgomery C; Roberts CA Exp Neurol; 2022 Jan; 347():113888. PubMed ID: 34624331 [TBL] [Abstract][Full Text] [Related]
12. Ecstasy (MDMA) and oral health. Brand HS; Dun SN; Nieuw Amerongen AV Br Dent J; 2008 Jan; 204(2):77-81. PubMed ID: 18268544 [TBL] [Abstract][Full Text] [Related]
13. [Acute and long-term effects of ecstasy]. Salzmann J; Marie-Claire C; Noble F Presse Med; 2004 Oct; 33(18 Suppl):24-32. PubMed ID: 15617173 [TBL] [Abstract][Full Text] [Related]
14. [3,4-methylenedioxymethamphetamine ('ecstasy'): its long-term emotional and cognitive effects, and serotonin depletion]. Molero-Chamizo A Rev Neurol; 2005 Jul 16-31; 41(2):108-14. PubMed ID: 16028190 [TBL] [Abstract][Full Text] [Related]
15. Functional Magnetic Resonance Imaging in Abstinent MDMA Users: A Review. Garg A; Kapoor S; Goel M; Chopra S; Chopra M; Kapoor A; McCann UD; Behera C Curr Drug Abuse Rev; 2015; 8(1):15-25. PubMed ID: 25731754 [TBL] [Abstract][Full Text] [Related]
16. Adverse symptomatology and suicide associated with the use of methylenedioxymethamphetamine (MDMA; "Ecstasy"). Cohen RS Biol Psychiatry; 1996 May; 39(9):819-20. PubMed ID: 8731525 [No Abstract] [Full Text] [Related]
17. Neurocognitive impairments in MDMA and other drug users: MDMA alone may not be a cognitive risk factor. Hanson KL; Luciana M J Clin Exp Neuropsychol; 2010 Apr; 32(4):337-49. PubMed ID: 20397296 [TBL] [Abstract][Full Text] [Related]
18. Long-term effects of 'ecstasy' abuse on the human brain studied by FDG PET. Buchert R; Obrocki J; Thomasius R; Väterlein O; Petersen K; Jenicke L; Bohuslavizki KH; Clausen M Nucl Med Commun; 2001 Aug; 22(8):889-97. PubMed ID: 11473208 [TBL] [Abstract][Full Text] [Related]
19. Cognitive deficits and cognitive normality in recreational cannabis and Ecstasy/MDMA users. Parrott A Hum Psychopharmacol; 2003 Mar; 18(2):89-90. PubMed ID: 12590401 [No Abstract] [Full Text] [Related]